Polycystic kidney disease: Kidney volume-a crystal ball for ADPKD prognosis?

Nature Reviews Nephrology

Volumn 10, Issue 9, 2014, Pages 485-486

  Gall, Emilie Cornec Le ^a   Le Meur, Yannick ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; OCTREOTIDE; RAPAMYCIN; TOLVAPTAN;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DETERIORATION; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; OUTCOME ASSESSMENT; PATIENT CODING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RENAL SYSTEM PARAMETERS; SHORT SURVEY; TOTAL KIDNEY VOLUME;

HUMANS; POLYCYSTIC KIDNEY DISEASES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS;

EID: 84906937219     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.132     Document Type: Short Survey

References (9)

1. Grantham, J. J. et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122-2130 (2006).
2. Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 479-486 (2012).
3. Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2013101138.
4. Mayo Foundation for Medical Education and Research. Classification of Typical ADPKD Calculator [online], http://www.mayo.edu/research/documents/pkd- center-adpkd-classification/doc-20094754.
5. Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830-840 (2010).
6. Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820-829 (2010).
7. Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407-2418 (2012).
8. Caroli, A. et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial. Lancet 382, 1485-1495 (2013).
9. Cornec-Le Gall, E. et al. Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. 24, 1006-1013 (2013).